No full-text available
To read the full-text of this research,
you can request a copy directly from the authors.
The efficacy and tolerance of high pressure oxygen combined with chemotherapy in postoperative patients with advanced gastric cancer
Abstract
Background: The aim of this study was to investigate the clinical efficacy analysis and tolerance observation of hyperbaric oxygen combined with chemotherapy in postoperative patients with advanced gastric cancer. Methods: A total of 56 patients from June 2014 to June 2015 with advanced gastric cancer postoperative chemotherapy were collected. These patients were randomly divided into the experimental group of 22 patients treated with hyperbaric oxygen combined with chemotherapy, and the control group of 23 patients treated with conventional chemotherapy. The results of imaging evaluation, tumor index, adverse reaction of chemotherapy and quality of life (QOL) were compared between the two groups. Results: The recurrence rate of 1 year imaging was 4.54% and 26.0% respectively in the experimental group and the control group, and the two groups had statistical differences (P=0.046); The persistent abnormal index of CA199, showed in the experimental group and the control group, accounting for 13.6% and 43.4% severally, which showed statistical differences (P=0.027); Compared with the control group, the incidence of hemocytopenia, thrombocytopenia, nausea and vomiting and peripheral nervous reaction were reduced in the experimental group, and there was a statistically significant difference between the two groups (P<0.05); The Quality of Life-Core 30 Questionnaire (QLQ-C30) score of the experimental group was 42.32±16.20, the control group was 79.53±18.54, and the life quality score of the experimental group was significantly lower than that of the control group (P<0.0001). There was no statistical difference between the two groups in hemoglobin and diarrhea (P>0.05). Conclusions: Hyperbaric oxygen combined with chemotherapy applied to postoperative chemotherapy for gastric cancer achieved good clinical effect, which reduced the recent local recurrence rate and the toxic side reaction, significantly improved the safety and tolerance of chemotherapy in patients.
Hypoxia in malignant tumors is a major factor in inducing the failure of clinical cancer treatment. Although several strategies have been developed to relieve hypoxia, most are still in the preclinical research phase. Therefore, hyperbaric oxygen (HBO), an approved adjuvant therapy for alleviating hypoxia clinically, is an excellent choice for enhancing the efficacy of cancer treatment that is impeded by tumor hypoxia. In this minireview, recent advances in HBO‐facilitated cancer treatment, including clinical applications and nanomedicine‐mediated cancer therapy are introduced. At the end of this minireview, the potential challenges faced by HBO therapy before clinical use are discussed. It is hoped that this review will provide a reference for future clinical research on the application of HBO in cancer treatment.
ResearchGate has not been able to resolve any references for this publication.